O'Donovan N - Search Results

1

Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomas.

O'Donovan N, Fischer A, Abdo EM, Simon F, Peter HJ, Gerber H, Buergi U, Marti U. O'Donovan N, et al. J Endocrinol. 2002 Sep;174(3):517-24. doi: 10.1677/joe.0.1740517. J Endocrinol. 2002. PMID: 12208673

2

Growth hormone regulates growth hormone receptor gene transcription in primary human thyroid cells.

Mullis PE, O'Donovan N, Eblé A, Marti U, Diem P, Bürgi U, Peter HJ. Mullis PE, et al. Mol Cell Endocrinol. 2000 Aug 30;166(2):111-9. doi: 10.1016/s0303-7207(00)00272-0. Mol Cell Endocrinol. 2000. PMID: 10996429

3

Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays.

O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M. O'Driscoll L, et al. Mol Cancer. 2006 Dec 15;5:74. doi: 10.1186/1476-4598-5-74. Mol Cancer. 2006. PMID: 17173689 Free PMC article.

4

Use of a panel of novel genes for differentiating breast cancer from non-breast tissues.

O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, Duffy MJ. O'Brien N, et al. Tumour Biol. 2007;28(6):312-7. doi: 10.1159/000115527. Epub 2008 Feb 5. Tumour Biol. 2007. PMID: 18253069

5

Alterations in integrin expression modulates invasion of pancreatic cancer cells.

Walsh N, Clynes M, Crown J, O'Donovan N. Walsh N, et al. J Exp Clin Cancer Res. 2009 Oct 13;28(1):140. doi: 10.1186/1756-9966-28-140. J Exp Clin Cancer Res. 2009. PMID: 19825166 Free PMC article.

6

Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.

O'Connor R, Clynes M, Dowling P, O'Donovan N, O'Driscoll L. O'Connor R, et al. Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):805-17. doi: 10.1517/17425255.3.6.805. Expert Opin Drug Metab Toxicol. 2007. PMID: 18028026 Review.

7

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.

Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. Glynn SA, et al. BMC Cancer. 2008 Jan 16;8:9. doi: 10.1186/1471-2407-8-9. BMC Cancer. 2008. PMID: 18199328 Free PMC article.

8

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.

Eustace AJ, Dowling P, Henry M, Doolan P, Meleady P, Clynes M, Crown J, O'Donovan N. Eustace AJ, et al. J Proteomics. 2011 Apr 1;74(4):490-501. doi: 10.1016/j.jprot.2010.12.011. Epub 2011 Jan 13. J Proteomics. 2011. PMID: 21237296

9

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, Clynes M, O'Connor R. Collins DM, et al. Invest New Drugs. 2010 Aug;28(4):433-44. doi: 10.1007/s10637-009-9266-0. Epub 2009 Jun 5. Invest New Drugs. 2010. PMID: 19499189

10

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N. Eustace AJ, et al. J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53. J Transl Med. 2008. PMID: 18823558 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters